Porcilis Ery Parvo vet.
Active substance
ATC code
Species
Pigs (sows and gilts).
Indications
For active immunisation of sows and gilts to prevent clinical signs of Erysipelas disease caused by all relevant Erysipelothrix rhusiopathiae serotypes (serotype 1 and 2) and for protection against embryonal and foetal death caused by porcine parvovirus (PPV) infection.
E. rhusiopathiae:
Onset of immunity: 3 weeks.
Duration of immunity: 6 months.
Porcine parvovirus (PPV):
Duration of immunity: 12 months.
Dose to be administered and administration route
Administer one dose of 2 ml by deep intramuscular injection behind the ear.
Before use, allow the vaccine to reach room temperature. Shake well before and regularly during use.
Use sterile vaccination equipment. Avoid introduction of contamination by multiple broaching.
Primary vaccination course:
Protection against E. rhusiopathiae and PPV should be achieved in gilts before first mating.
To induce protection against erysipelas, a double vaccination as a primary vaccination course is advised. This can be achieved with the monovalent erysipelas vaccine (Porcilis Ery) either 4 weeks before or 4 weeks after use of this combined erysipelas and PPV vaccine.
A single injection not later than 2 weeks before mating is sufficient to protect the following pregnancy from damage due to PPV.
To avoid possible interference from maternal antibodies the pigs should be 6 months old before vaccination to ensure efficacy against PPV.
Revaccinations:
Revaccinations should be administered once a year, supplemented with the administration of the monovalent erysipelas vaccine (Porcilis Ery), 6 months after use of this combined erysipelas and PPV vaccine.
Adverse reactions
Transient increases in body temperature (0.5 °C) within 24 hours may very commonly occur.
Mild transient local swelling (Ø 1 – 10 mm) until 8 days after vaccination may very commonly occur.
Transient reluctance to move may commonly occur.
In post marketing experienceIn very rare cases, a hypersensitivity reaction may occur.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
